With ERLEADA® + ADT, the TITAN final analysis shows you can extend life and offer additional clinical benefits vs. placebo + ADT.[1]a
aPatients with severe angina, myocardial infarction, congestive heart failure, arterial or venous thromboembolic events, a history of or predisposition to seizure, or recent ventricular arrhythmias were excluded.[2]
An IPCW crossover analysis of OS was performed to adjust for the 208 patients in the placebo + ADT group that crossed over to ERLEADA® + ADT treatment at unblinding.[1]
Adapted from Chi KN, et al. 2021.
bOS and rPFS were dual primary endpoints of the TITAN study.[2]
Adapted from Chi KN, et al. 2021.
The IPCW model is frequently used to correct for bias of crossover patients in oncology trials.[3]
Treating early with ERLEADA® + ADT gives your mHSPC patients the chance to live longer.[2]
Adapted from Chi KN, et al. 2019.
crPFS: time from randomisation to first imaging-based documentation of progressive disease or death, whichever occurred first.[2]
ERLEADA® + ADT maintains benefits through to the next line of therapy, significantly reducing the risk of PFS2 or death on the subsequent treatment compared with placebo + ADT.[1]
In the TITAN study, PFS2 was defined as time from randomisation to the first occurrence of investigator-determined disease progression (PSA progression, progression on imaging or clinical progression) on first subsequent therapy or death.[2]
Adapted from Chi KN, et al. 2021.
Treat early with ERLEADA® + ADT to delay time to initiation of cytotoxic chemotherapy.[1]
ERLEADA® + ADT prolonged median time to PSA progression compared with placebo + ADT.[1]
Adapted from Chi KN, et al. 2021.
dTime to PSA progression: time from randomisation to date of PSA progression based on Prostate Cancer Working Group 2 criteria.
The secondary endpoints of time to pain progression, time to chronic opioid use, and time to skeletal-related event all favoured ERLEADA® + ADT over placebo + ADT.[1]
Click below to find out more about the clinical benefits with ERLEADA® + ADT:
Give patients with mHSPC the opportunity for an additional treatment option upon disease progression[1][2]
Extend life across a broad range of mHSPC patients with ERLEADA® + ADT[1]
Push back on progression and maintain QoL in mHSPC[1]
ADT, androgen deprivation therapy. CI, confidence interval. EMA, European Medicines Agency. HR, hazard ratio. IPCW, inverse probability of censoring weighting. ITT, intention-to-treat. mCRPC, metastatic castration-resistant prostate cancer. mHSPC, metastatic hormone-sensitive prostate cancer. OS, overall survival. PFS2, second progression-free survival. PSA, prostate-specific antigen. QoL, quality of life. rPFS, radiographic progression-free survival.
▼ Este medicamento está sujeito a monitorização adicional. Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.
Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.
Antes de prescrever consulte o RCM completo.
RCM de Erleada®, veja aqui